Steven M. Ewer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steven M. Ewer has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alma Farooque
University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
1 shared publication - Amye J. Tevaarwerk
Department of Oncology, Mayo Clinic, Rochester, MN
1 shared publication - Cathy Lee-Miller
Division of Hematology Oncology, Transplant and Cellular Therapy Department of Pediatrics University of Wisconsin Madison Wisconsin USA
1 shared publication - Cibele Barbosa Carroll
University of Wisconsin Carbone Cancer Center, Madison, WI
1 shared publication David D. Pham
Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
1 shared publication- Fauzia Osman
Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
1 shared publication
Latest Publications
- 1 June 2023
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 12 (3) , 331-339
Pre-Treatment Left Ventricular Ejection Fraction Assessment and Long-Term Cardiovascular Outcomes in Adolescent and Young Adult Lymphoma Survivors
Purpose: Anthracyclines can cause long-term cardiovascular (CV) morbidity, especially in long-term Adolescent and Young Adult (AYA) lymphoma survivors. Pre-treatment left ventricular ejection fraction (LVEF) evaluation is recommended, although its utility in AYA is not established. We sought to determine the pre-treatment LVEF assessment practices in AYA lymphoma survivors treated with anthracyclines and factors associated with long-term cardiotoxicity. Methods: Through an electronic health records review, we retrospectively identified AYA lymphoma survivors with ≥5 years of follow-up postanthracycline treatment. Pre-treatment and follow-up data were abstracted. CV health conditions were defined as risk factors for CV disease and confirmed CV diagnoses. Survivors who had new CV health conditions at follow-up were compared to those who were not using descriptive statistics and logistic regression. Results: One hundred fifteen AYA lymphoma survivors met the study criteria. Pre-treatment LVEF assessment did not affect chemotherapy decisions. Survivors with pre-treatment CV evaluation had mean follow-up since diagnosis of 8 ± 3.3 years, while survivors without it had 10.3 ± 4.2 years, p < 0.05. Survivors with pre-treatment LVEF assessment received lower cumulative anthracycline dose (240.4 mg/m 2 vs. 280.1 mg/m 2 , p < 0.05) and fewer cycles of chemotherapy (4.8 ± 1.5 vs. 5.6 ± 1.2, p < 0.05). Body mass index (BMI) category at diagnosis and follow-up, in addition to age were associated with development of new CV health conditions, pre-treatment LVEF evaluation was not. Conclusion: Pre-treatment LVEF assessment for AYA lymphoma survivors does not impact oncologic treatment decisions or development of CV health conditions. It may be more valuable to assess and modify CV risk factors such as BMI for CV disease prevention.
- 1 June 2023
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 12 (3) , 331-339
Pre-Treatment Left Ventricular Ejection Fraction Assessment and Long-Term Cardiovascular Outcomes in Adolescent and Young Adult Lymphoma Survivors
Purpose: Anthracyclines can cause long-term cardiovascular (CV) morbidity, especially in long-term Adolescent and Young Adult (AYA) lymphoma survivors. Pre-treatment left ventricular ejection fraction (LVEF) evaluation is recommended, although its utility in AYA is not established. We sought to determine the pre-treatment LVEF assessment practices in AYA lymphoma survivors treated with anthracyclines and factors associated with long-term cardiotoxicity. Methods: Through an electronic health records review, we retrospectively identified AYA lymphoma survivors with ≥5 years of follow-up postanthracycline treatment. Pre-treatment and follow-up data were abstracted. CV health conditions were defined as risk factors for CV disease and confirmed CV diagnoses. Survivors who had new CV health conditions at follow-up were compared to those who were not using descriptive statistics and logistic regression. Results: One hundred fifteen AYA lymphoma survivors met the study criteria. Pre-treatment LVEF assessment did not affect chemotherapy decisions. Survivors with pre-treatment CV evaluation had mean follow-up since diagnosis of 8 ± 3.3 years, while survivors without it had 10.3 ± 4.2 years, p < 0.05. Survivors with pre-treatment LVEF assessment received lower cumulative anthracycline dose (240.4 mg/m 2 vs. 280.1 mg/m 2 , p < 0.05) and fewer cycles of chemotherapy (4.8 ± 1.5 vs. 5.6 ± 1.2, p < 0.05). Body mass index (BMI) category at diagnosis and follow-up, in addition to age were associated with development of new CV health conditions, pre-treatment LVEF evaluation was not. Conclusion: Pre-treatment LVEF assessment for AYA lymphoma survivors does not impact oncologic treatment decisions or development of CV health conditions. It may be more valuable to assess and modify CV risk factors such as BMI for CV disease prevention.
Late‐onset heart failure after treatment for breast cancer
Late‐onset heart failure after breast cancer is a rare event. It is necessary to remain vigilant for cardiac complications after potentially toxic cancer treatments.
Late‐onset heart failure after treatment for breast cancer
Late‐onset heart failure after breast cancer is a rare event. It is necessary to remain vigilant for cardiac complications after potentially toxic cancer treatments.
- 1 January 2018
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 13 (1) , 62-63
Guest Editorial: Is Cardio-oncology Ready for Algorithms?
Two recent publications have sought to provide some authoritative guidance regarding the management of patients undergoing potentially cardiotoxic treatments: the 2016 European Society of Cardiology (ESC)
- 1 January 2018
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 13 (1) , 62-63
Guest Editorial: Is Cardio-oncology Ready for Algorithms?
Two recent publications have sought to provide some authoritative guidance regarding the management of patients undergoing potentially cardiotoxic treatments: the 2016 European Society of Cardiology (ESC)
- 1 June 2015
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 36 (6) , 321-322
The anthracycline–trastuzumab interaction: a lesson in not jumping to confusion
- 1 June 2015
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 36 (6) , 321-322
The anthracycline–trastuzumab interaction: a lesson in not jumping to confusion